Currency effect amplifies Abilify's growth for Otsuka
This article was originally published in Scrip
Executive Summary
Otsuka Holdings saw global sales of its top product, the atypical antipsychotic Abilify (aripiprazole), increase by 22% to JPY117.8bn ($1.22bn) in the fiscal first quarter ended 30 June, helped by currency effects and US growth.